Wolfgang Jungraithmayr | Medicine and Dentistry | Lifetime Achievement Award

Lifetime Achievement Award

Wolfgang Jungraithmayr
University Hospital of Rostock, Germany

Wolfgang Jungraithmayr
Researcher Wolfgang Jungraithmayr
Affiliation University Hospital of Rostock
Country Germany
Scopus ID 25621008100
Documents 129
Citations 2,929
h-index 28
Subject Area Medicine and Dentistry
Event International Phenomenological Research Awards
ORCID 0000-0002-1442-4862

Wolfgang Jungraithmayr, MD, PhD, is a German thoracic surgeon, clinician-scientist, educator, and academic leader serving as Chair and Full Professor of Thoracic Surgery at the University Hospital of Rostock. His research portfolio spans lung transplantation, thoracic oncology, immunology, translational medicine, and experimental surgery. He is particularly recognized for pioneering the orthotopic mouse lung transplantation model and for advancing translational research into lung cancer immunotherapy and transplant immunology.[1]

Abstract

This article evaluates the scholarly achievements, research leadership, educational contributions, and international influence of Wolfgang Jungraithmayr in the fields of thoracic surgery, lung transplantation, and translational oncology. His work integrates clinical practice with experimental science, contributing to advances in transplant immunology, lung cancer therapeutics, and surgical innovation. Through sustained research productivity, competitive grant acquisition, international collaboration, and extensive scientific mentorship, he has established a distinguished academic profile suitable for consideration for lifetime recognition within the biomedical sciences.[1]

Keywords

Thoracic Surgery; Lung Transplantation; Lung Cancer; Immunology; Translational Medicine; CD26; Experimental Surgery; Academic Leadership; Oncology; Lifetime Achievement.

Introduction

Wolfgang Jungraithmayr has developed an interdisciplinary academic career combining thoracic surgical practice, translational biomedical research, and university-level education. Following medical training in Germany and advanced specialization in Switzerland, he completed doctoral research in immunology at the University and ETH Zurich. His subsequent appointments included leadership positions at the University Hospital Zurich, Medical University Brandenburg, and University Hospital Rostock, where he currently serves as Chair of Thoracic Surgery.[2]

His scientific activities have focused on improving outcomes in lung transplantation, understanding immune-mediated disease mechanisms, and identifying novel therapeutic targets for thoracic malignancies. These efforts have produced a substantial body of peer-reviewed literature and attracted significant competitive funding from European research agencies.[1]

Research Profile

Wolfgang Jungraithmayr’s research program centers on lung transplantation biology, transplant tolerance, tumour immunology, and translational thoracic oncology. A major contribution of his laboratory has been the establishment and dissemination of the orthotopic mouse lung transplantation model, which has become a valuable experimental platform for investigating immune responses, rejection mechanisms, and therapeutic interventions across multiple disciplines.[3]

His laboratory has secured more than €3.2 million in competitive research funding, including support from the German Research Foundation (DFG), Swiss National Science Foundation (SNSF), and other major funding bodies. Research projects have addressed chronic lung allograft dysfunction, immune regulation, magnetic resonance imaging applications, angiogenesis, and targeted immunotherapeutic approaches against lung adenocarcinoma.[1]

Research Contributions

Wolfgang Jungraithmayr’s principal research contributions include pioneering murine lung transplantation models, advancing transplant immunology, investigating immune tolerance mechanisms, identifying novel therapeutic targets in lung cancer, and improving understanding of ischemia-reperfusion injury and chronic allograft dysfunction.[2][4][5][6]

Publications

Recent publications highlight Jungraithmayr’s contributions to transplantation immunology, lung transplant outcomes, ischemia-reperfusion injury, and experimental models of chronic allograft dysfunction, demonstrating sustained impact in thoracic surgery and translational research.[2][3][4][5][6]

Wolfgang Jungraithmayr has authored more than 160 scientific publications and maintains a sustained record of peer-reviewed research. Representative publications reflect his contributions to lung transplantation, transplant immunology, and thoracic oncology.[1]

Research Impact

According to Scopus metrics, Jungraithmayr has accumulated 129 indexed documents, 2,929 citations, and an h-index of 28. These indicators demonstrate sustained scholarly influence within thoracic surgery, transplantation science, and oncology research.[1]

Beyond publication metrics, his impact is reflected through international teaching initiatives, reviewer responsibilities for leading journals, grant-review service for major funding agencies, editorial board memberships, and mentorship of emerging clinicians and scientists. His laboratory has trained investigators from numerous institutions across Europe, North America, and Asia, thereby extending the global reach of his methodological innovations.[1]

Award Suitability

Several factors support consideration of Wolfgang Jungraithmayr for a Lifetime Achievement Award. These include his longstanding record of scientific productivity, leadership of internationally recognized research programs, establishment of innovative experimental models, successful acquisition of competitive funding, extensive educational activities, and receipt of numerous international scientific distinctions. His contributions have influenced both clinical practice and experimental biomedical research, particularly in thoracic surgery and transplantation science.[1]

The cumulative scope of his achievements illustrates a sustained commitment to advancing medical knowledge, supporting scientific collaboration, and fostering the development of future generations of clinician-scientists.[2]

Conclusion

Wolfgang Jungraithmayr represents a notable figure in contemporary thoracic surgery and translational medicine. Through pioneering research, academic leadership, international educational engagement, and sustained scientific productivity, he has contributed significantly to the advancement of lung transplantation and thoracic oncology. His record of achievement, influence, and service provides a strong basis for recognition within the framework of a Lifetime Achievement Award.[1]

References

  1. Elsevier. (n.d.). Scopus Author Details: Wolfgang Jungraithmayr, Author ID 25621008100. Scopus. https://www.scopus.com/authid/detail.uri?authorId=25621008100
  2. Ohm B, Giannou AD, Harriman DI, Jungraithmayr WM, Zazara DE, et al. (2025). Chimerism and Immunological Tolerance in Solid Organ Transplantation. Immunologic Research. https://link.springer.com/article/10.1007/s00281-025-01052-x
  3. Moneke I, Ogutur ED, Kornyeva A, Jungraithmayr WM, Frye BC, et al. (2024). Donor Age Over 55 Is Associated With Worse Outcome in Lung Transplant Recipients With Idiopathic Pulmonary Fibrosis. BMC Pulmonary Medicine, 2024. https://link.springer.com/article/10.1186/s12890-024-03317-x
  4. Sander ML, Eulenburg V, Maeyashiki T, Jungraithmayr WM, Piegeler T, et al. (2024). Remote Kidney and Liver Injury After Transplantation of Lung Allografts in an Allogeneic Mouse Model. Transplantation Proceedings, 2024. DOI: https://doi.org/10.1016/j.transproceed.2024.10.020
  5. Coppens A, Verleden SE, Claes E, Voet H, Verleden GM, Lapperre TS, Yildirim AΓ–, et al. (2024). Murine Orthotopic Lung Transplant Models: A Comprehensive Overview of Genetic Mismatch Degrees and Histopathological Insights Into Chronic Lung Allograft Dysfunction. American Journal of Transplantation, 2024. DOI: https://doi.org/10.1016/j.ajt.2024.07.033
  6. Jungraithmayr W. (2020). Novel Strategies for Endothelial Preservation in Lung Transplant Ischemia-Reperfusion Injury. Frontiers in Physiology, 2020. DOI: https://doi.org/10.3389/fphys.2020.581420

Bing Han | Medicine and Dentistry | Outstanding Scientist Award

Dr.Bing Han | Medicine and Dentistry | Outstanding Scientist AwardΒ 

Dermatologist atΒ The First Hospital of Jilin University |Β China

Dr. Bing Han is a medical researcher and clinician specializing in dermatological science with a strong foundation in advanced medical education and academic training. Dr. Bing Han has extensive professional experience integrating clinical practice with translational research, focusing on melanoma, vitiligo, and molecular mechanisms of skin disease progression. The research interests emphasize biomarker discovery, metabolic reprogramming, and therapeutic innovation in dermatology. With 99 scholarly documents, 1,291 citations from 1,231 documents, and an h-index of 22, Dr. Bing Han demonstrates sustained scientific impact and excellence in medical research.

Citation Metrics (Scopus)

1400

1000

600

200

0

Citations
1,291

Documents
99

h-index
22


View Scopus Profile

Featured Publications

Cristina Maria Del Prete | Medicine and Dentistry | Women Researcher Award

Dr. Cristina Maria Del Prete | Medicine and Dentistry | Women Researcher AwardΒ 

Rehabilitation Department Chair atΒ Local Health AuthorityΒ Italy

Dr. Cristina Maria Del Prete is a recognized professional in the field of Physical and Rehabilitation Medicine, known for her commitment to advancing innovative healthcare models, interdisciplinary rehabilitation practices, and measurable improvements in patient quality of life. She completed comprehensive medical education and specialized training in rehabilitation medicine, followed by multiple advanced executive and managerial qualifications focused on healthcare systems, organizational leadership, digital transformation, and strategic management. Her education laid a strong foundation for a career that has spanned clinical practice, healthcare administration, academic teaching, and national health policy participation. Over the years, she has held progressive leadership roles within major public healthcare structures, directing rehabilitation departments, coordinating multidisciplinary teams, and overseeing complex service networks involving hospital- and community-based rehabilitation centers. Her responsibilities have included workforce management, budget oversight, strengthening patient-care pathways, improving standards of disability support, and enhancing regional service delivery in alignment with evolving healthcare regulations. She has also actively contributed to national and regional scientific boards, steering committees, and professional societies focused on improving spasticity management, supporting patients with neurological conditions, addressing musculoskeletal pain, and advancing gender-inclusive perspectives within modern healthcare. Her research output reflects a strong blend of clinical relevance and academic rigor, focusing on post-stroke rehabilitation, botulinum toxin interventions in neuromotor disorders, gait analysis, scoliosis management, family coping mechanisms in the context of disability, and the psychological dynamics influencing care outcomes. Her published studies in international peer-reviewed journals demonstrate a dedication to evidence-based rehabilitation, resulting in 63 citations from 55 documents, 7 published scientific works, and an h-index of 4. She has also contributed extensively to academic progress through university teaching appointments across multiple medical programs, where she has trained students in foundational and advanced principles of rehabilitation medicine. International clinical training and professional development programs have further enhanced her expertise and broadened her exposure to advanced rehabilitative technologies, patient-centered methodologies, and global best practices. Throughout her career, she has remained consistently committed to improving health system performance, innovating care delivery frameworks, and conducting research that informs more efficient, equitable, and clinically effective rehabilitation services. Her professional journey reflects a continuous dedication to advancing healthcare quality, supporting both patients and practitioners, and strengthening the scientific foundations of modern rehabilitation.

Featured Publications:

Del Prete, C. M. (2025). Determinants of sibling relationships in the context of mental disorders. PLoS One.

Del Prete, C. M. (2025). Siblings of persons with disabilities: A systematic integrative review of the empirical literature. Clinical Child and Family Psychology Review.

Del Prete, C. M. (2023). Parentification, distress, and relationships with parents as factors shaping relationships in families with disability. Frontiers in Psychiatry.

Del Prete, C. M. (2022). An observational cross-sectional study of gender and disability as determinants of person-centered medicine in botulinum neurotoxin treatment of upper motoneuron syndrome. Toxins.

Del Prete, C. M. (2022). Brace treatment in adolescent idiopathic scoliosis: A rehabilitative point of view. International Journal of Environmental Research and Public Health.

Del Prete, C. M. (2021). Early botulinum toxin type A injection for post-stroke spasticity: A longitudinal cohort study. Toxins.

Del Prete, C. M. (2022). Efficacy of ultrasound-guided percutaneous lavage and biocompatible electrical neurostimulation in calcific rotator cuff tendinopathy. International Journal of Environmental Research and Public Health.

Del Prete, C. M. (2004). Conservative rehabilitative treatment of facial nerve injuries: A critical literature review. Europa Medicophysica.

Del Prete, C. M. (2002). Outcome research in adults with neurological disability. Europa Medicophysica.

Del Prete, C. M. (2001). Therapeutic water exercise in patients with hip arthroplasty. Europa Medicophysica.

Victor Adepoju | Global Health | Excellence in Research

Dr. Victor Adepoju | Global Health | Excellence in Research

Director, Infectious diseases and Research at Jhpiego, Nigeria.

Dr. Victor Adepoju is a distinguished public health physician, researcher, and strategic information expert with over 14 years of experience managing large-scale global health programs across various income settings. As a Portfolio Director at Jhpiego, an affiliate of Johns Hopkins University, he leads multi-million-dollar projects in infectious diseases, maternal health, and immunization. With expertise in TB, HIV, viral hepatitis, and health systems strengthening, he has over 70 peer-reviewed publications and has contributed to WHO guidelines. Fluent in English and Yoruba, he is a global health leader driving universal health coverage and healthcare innovation.

Professional Profile:

Google Scholar

Education & Experience πŸŽ“πŸ’Ό

  • MBChB (Bachelor of Medicine & Surgery) – Obafemi Awolowo University πŸ₯
  • MSc (International Management of Health Systems) – University of Liverpool 🌍
  • Master Certificate in Healthcare Leadership – Cornell University 🎯
  • PhD (Public Health) – Crown International University πŸ†
  • Portfolio Director, Jhpiego (Johns Hopkins University Affiliate) (2021–Present) 🌍
  • Over 14 years in global health, working with USAID, Global Fund, GAVI, and UNITAID πŸ’‘

Professional Development πŸ“ˆπŸ©Ί

Dr. Adepoju is a seasoned expert in global health implementation, policy, and research. He has designed and led health interventions for TB, HIV, maternal and child health, and neglected tropical diseases, securing over $100 million in funding. His work in operational research, health systems strengthening, and digital health innovations has shaped policies globally. With experience in capacity building, health financing, and universal health coverage, he has collaborated with Ministries of Health, civil society, and donors. A thought leader in market shaping, he drives equitable access to healthcare solutions for vulnerable populations worldwide.

Research Focus πŸ”¬πŸ“š

Dr. Adepoju’s research spans infectious diseases (HIV, TB, viral hepatitis, COVID-19, and mpox), neglected tropical diseases, and maternal, newborn, and child health (MNCH). His expertise extends to universal health coverage, health systems strengthening, and innovative diagnostics. He is a leader in market shaping, improving access to essential medicines and vaccines in low- and middle-income countries (LMICs). His work also includes health financing, strategic information, and public-private partnerships. His contributions to implementation science have shaped WHO policies and national health guidelines across multiple regions.

Awards & Honors πŸ…πŸŽ–

  • An Excellence in Global Health Leadership Award πŸŒπŸ†
  • USAID/Global Fund Project Recognition Award πŸ₯πŸ’‘
  • Jhpiego Outstanding Leadership Award πŸ…
  • Best Public Health Research Paper Award πŸ“–
  • UNITAID Health Innovation Award πŸ’‰
  • Certificate of Excellence in Health Systems Strengthening πŸ†
  • Recognition for Policy Contribution to WHO Guidelines πŸ“œ

Publication Top Notes

πŸ“„ Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021 – The Lancet 402 (10397), 203-234 πŸ“… 2023 πŸ” Cited by: 1972

πŸ“„ Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories, 1990–2021 – The Lancet 403 (10440), 2133-2161 πŸ“… 2024 πŸ” Cited by: 566

πŸ“„ Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 – The Lancet 403 (10440), 2100-2132 πŸ“… 2024 πŸ” Cited by: 530

πŸ“„ Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic – The Lancet 403 (10440), 1989-2056 πŸ“… 2024 πŸ” Cited by: 321

πŸ“„ The burden of bacterial antimicrobial resistance in the WHO African region in 2019: a cross-country systematic analysis – The Lancet Global Health 12 (2), e201-e216 πŸ“… 2024 πŸ” Cited by: 112

πŸ“„ Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021 – The Lancet 403 (10440), 2057-2099 πŸ“… 2024 πŸ” Cited by: 97

πŸ“„ Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021 – The Lancet Infectious Diseases 24 (9), 974-1002 πŸ“… 2024 πŸ” Cited by: 60

πŸ“„ Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the Global Burden of Disease Study 2019 – EClinicalMedicine 64 πŸ“… 2023 πŸ” Cited by: 54

πŸ“„ Prevalence of rifampicin-resistant tuberculosis and associated factors among presumptive tuberculosis patients in a secondary referral hospital in Lagos, Nigeria – African Health Sciences 18 (3), 472-478 πŸ“… 2018 πŸ” Cited by: 48

πŸ“„ Childhood tuberculosis in Nigeria: disease presentation and treatment outcomes – Health Services Insights 11, 1178632918757490 πŸ“… 2018 πŸ” Cited by: 40